tiprankstipranks
Oxford BioDynamics Continues Genomic Diagnostic Innovations
Company Announcements

Oxford BioDynamics Continues Genomic Diagnostic Innovations

Oxford BioDynamics (GB:OBD) has released an update.

Don't Miss our Black Friday Offers:

Oxford BioDynamics, a pioneer in precision clinical diagnostics, was recently in the news for its involvement in the UK Cancer Immunotherapy Response Research Platform (CIRRP) funding bid. Although the company’s EpiSwitch consortium was not awarded the funding, OBD remains committed to the advancement of its Checkpoint Inhibitor Response Test (CiRT) and continues to innovate in the field of genomics-based diagnostics. The company boasts a growing portfolio of tests, including their highly accurate CiRT, aimed at improving personalized healthcare.

For further insights into GB:OBD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskOxford BioDynamics Issues Shares to Preserve Cash
TipRanks UK Auto-Generated NewsdeskOxford BioDynamics Unveils Promising COVID Severity Test
TipRanks UK Auto-Generated NewsdeskOxford BioDynamics Gains Key Clinical Approval
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App